Paeameter ranges and optimal values. by Zhen Zhao (159931)

“…Firstly, recursive feature elimination using cross validation (RFECV), maximum information coefficient (MIC), and mean decrease accuracy (MDA) methods were utilized to select population distribution feature factors. …”

Improved random forest algorithm. by Zhen Zhao (159931)

“…Firstly, recursive feature elimination using cross validation (RFECV), maximum information coefficient (MIC), and mean decrease accuracy (MDA) methods were utilized to select population distribution feature factors. …”

Datasets used in the study area. by Zhen Zhao (159931)

“…Firstly, recursive feature elimination using cross validation (RFECV), maximum information coefficient (MIC), and mean decrease accuracy (MDA) methods were utilized to select population distribution feature factors. …”

Evaluation of the improved random forest model. by Zhen Zhao (159931)

“…Firstly, recursive feature elimination using cross validation (RFECV), maximum information coefficient (MIC), and mean decrease accuracy (MDA) methods were utilized to select population distribution feature factors. …”

Comparison of model metrics. by Zhen Zhao (159931)

“…Firstly, recursive feature elimination using cross validation (RFECV), maximum information coefficient (MIC), and mean decrease accuracy (MDA) methods were utilized to select population distribution feature factors. …”

Flowchart of population spatialization. by Zhen Zhao (159931)

“…Firstly, recursive feature elimination using cross validation (RFECV), maximum information coefficient (MIC), and mean decrease accuracy (MDA) methods were utilized to select population distribution feature factors. …”

Longer polyQ sequences decrease the nuclear localization of AR in the absence of hormone. by Carlos M. Roggero (11909585)

Titanate Nanosheets/Cellulose Composite Showing Improved Crystallinity and Decreased Water Wettability by Gamma-Irradiation by Yaowaluk Tariwong (22630109)

Loss of cytoplasmic incompatibility in <i>Wolbachia</i>-infected <i>Aedes aegypti</i> under field conditions by Perran A. Ross (844275)

“…In a second experiment under somewhat hotter conditions (>40°C in 50% shade), field-reared <i>w</i>Mel-infected females had their egg hatch reduced to 25% when crossed to field-reared <i>w</i>Mel-infected males. …”

Sensitivity analysis of 50:50 model. by Rachael Miller Neilan (10678614)

“…<p>A sensitivity analysis was conducted on the 50:50 model with constant 120 pA current to determine the sensitivity of pain output to select model parameters before injury (t = 10), during injury (t = 105), and after injury (t = 240). …”

Projection of testing costs under different cost scenarios for medical supplies and personnel (USD). by Nelmo Jordão Manjate (16324619)

Subjects:

Summary of resources per type of test and costs for Ag-RDT tests (USD 2020). by Nelmo Jordão Manjate (16324619)

Subjects:

Unit cost per test type and per health facility for diagnosis of SARS-CoV-2 by Ag-RDT and RT-PCR. by Nelmo Jordão Manjate (16324619)

Subjects:

Average value of cost components composing the unit cost (in USD) of SARS-CoV-2 diagnosis per per device type. by Nelmo Jordão Manjate (16324619)

Subjects:

Control group common bigram words (Top 50) before and after pandemic. by Yuxuan Cai (19226202)

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”